Meloxicam Cyclodextrin Inclusion Complex for Rapid Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief, which can be addressed by forming an inclusion complex with cyclodextrins to enhance solubility and absorption.
Innovation Solution
The formation of an inclusion complex of meloxicam with cyclodextrins, such as sulfobutylether β-cyclodextrin (SBEβCD), and a bicarbonate, like sodium bicarbonate, to increase solubility and bioavailability, allowing for faster absorption and extended plasma concentration half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If meloxicam is administered in conventional formulations, then the drug can be delivered orally, but the poor aqueous solubility reduces bioavailability and slows onset of pain relief
Solution Approach 1:
The patent employs cyclodextrins as intermediary carriers that form inclusion complexes with meloxicam. The cyclodextrin cavity encapsulates the hydrophobic meloxicam molecule, presenting a hydrophilic exterior to aqueous environments, thereby mediating between the insoluble drug and the aqueous biological fluids to enhance solubility and absorption
Solution Approach 2:
The patent modifies the physical-chemical parameters of meloxicam by forming inclusion complexes that alter its solubility characteristics. The complexation changes the apparent solubility, dissolution rate, and bioavailability parameters of meloxicam without changing its chemical structure, enabling improved pharmacokinetic performance
2Speed
If conventional meloxicam formulations are used, then the dosage form is simple, but the onset of pain relief is slow
Solution Approach 1:
Cyclodextrins serve as intermediary carriers that accelerate the dissolution and absorption of meloxicam by solubilizing it in aqueous gastric fluids, thereby speeding up the onset of therapeutic effect without requiring complex delivery systems or multiple administration steps
3Duration of action of moving object
If meloxicam is administered without solubility enhancement, then the formulation is straightforward, but the plasma concentration half-life is reduced
Solution Approach 1:
The cyclodextrin inclusion complex acts as a sustained-release intermediary, maintaining meloxicam in solubilized form throughout the gastrointestinal tract and enabling prolonged absorption. This extends the plasma concentration half-life by continuous release from the cyclodextrin carrier rather than rapid elimination of conventional formulations
Solution Approach 2:
The formulation modifies the pharmacokinetic parameters of meloxicam by altering its dissolution and absorption profile through cyclodextrin complexation, resulting in extended half-life and sustained plasma concentrations without requiring controlled-release mechanisms or complex dosing regimens
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly enhances the oral bioavailability and absorption rate of meloxicam, providing rapid pain relief and sustained efficacy for conditions like migraine and arthritis, with improved pharmacokinetic parameters compared to commercial meloxicam formulations.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
Cyclodextrins are hydrophobic on the inside and hydrophilic on the inside which helps to facilitate the transport of molecules
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.